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Abstract
Background: Over the last few decades, biomedical HIV prevention research had engaged multiple African
stakeholders. There have however been few platforms to enable regional stakeholders to engage with one
another. In partnership with the World AIDS Campaign International, the Institute of Public Health of Obafemi
Awolowo University, and the National Agency for the Control of AIDS in Nigeria, the New HIV Vaccine and
Microbicide Advocacy Society hosted a forum on biomedical HIV prevention research in Africa. Stakeholders’
present explored evidences related to biomedical HIV prevention research and development in Africa, and made
recommendations to inform policy, guidelines and future research agenda.
Discussion: The BHPF hosted 342 participants. Topics discussed included the use of antiretrovirals for HIV
prevention, considerations for biomedical HIV prevention among key populations; HIV vaccine development; HIV
cure; community and civil society engagement; and ethical considerations in implementation of biomedical HIV
prevention research. Participants identified challenges for implementation of proven efficacious interventions and
discovery of other new prevention options for Africa. Concerns raised included limited funding by African
governments, lack of cohesive advocacy and policy agenda for biomedical HIV prevention research and
development by Africa, varied ethical practices, and limited support to communities’ capacity to actively engaged
with clinical trial conducts. Participants recommended that the African Government implement the Abuja +12
declaration; the civil society build stronger partnerships with diverse stakeholders, and develop a coherent
advocacy agenda that also enhances community research literacy; and researchers and sponsors of trials on the
African continent establish a process for determining appropriate standards for trial conduct on the continent.
Conclusion: By highlighting key considerations for biomedical HIV prevention research and development in Africa,
the forum has helped identify key advocacy issues that Civil Society can expend efforts on so as to strengthen
support for future biomedical HIV prevention research on the continent.
Introduction
The New HIV Vaccine and Microbicide Advocacy Society
and the World AIDS Campaign International in collabora-
tion with the Institute of Public Health, Obafemi Awolowo
University, Ile-Ife Nigeria and the National Agency for the
Control of AIDS, Nigeria convened the 2013 Biomedical
HIV Prevention Forum (BHPF) on 18th and 19th Novem-
ber, 2013 in Abuja, Nigeria [1]. The forum was the first of a
series of conferences on biomedical HIV prevention
research and development in Africa. Participants included
international and regional researchers, programme man-
agers, government officials, laboratory scientists, policy
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The BHPF created a platform for sharing different
perspectives and experiences in HIV prevention, and
provided opportunities for networking that enabled key
players in the HIV prevention field in Africa to be more
effective in their efforts to halt the epidemic. The BHPF
also served as a platform for forging new connections
across the interdependent fields of HIV programming
(prevention, treatment, care and support); policy and
advocacy; human rights; by linking researchers, care
providers, policy makers, advocates, and people living
with and affected by HIV. The ultimate goal of the lin-
kages facilitated by the forum was to promote synergy
between biomedical HIV prevention science, HIV pro-
gramming, and civil society engagement. By highlighting
both successes and gaps in the contribution of biomedi-
cal research to integrated country-led HIV prevention
responses, the BHPF helped articulate a new agenda for
biomedical HIV prevention research, including new
areas of research and intervention, policy implications
and evaluation, and civil society-led advocacy.
Discussion
The BHPF hosted 342 participants from South Africa,
Kenya, the United States, and Australia, with most parti-
cipants (94.2%) from Nigeria. Four daily sessions
included expert presentations at plenaries, roundtables
and symposia. Topics discussed included the use of anti-
retrovirals for HIV prevention, considerations for bio-
medical HIV prevention among key populations (men
who have sex with men (MSM), female sex workers
(FSW), people who inject drugs (PWID), sero-discordant
couples, young women); HIV vaccine development; HIV
cure and prospect for ending the HIV epidemic; com-
munity and civil society engagement in biomedical HIV
prevention; and ethical considerations for the design
and implementation of biomedical HIV prevention
research. Each session included opportunities for dialo-
gue in which participants shared insight from their own
knowledge and experience with the issues discussed.
A short powerpoint summary of the BHPF has been
disseminated through existing national and international
networks of the forum organisers, and is available from
the New HIV Vaccine and Microbicide Advocacy
Society. The current article provides specific details, and
summarizes the specific changes or action steps identi-
fied by participants to enhance the potential impact of
biomedical HIV prevention research in halting the epi-
demic. These action steps targeted all stakeholders,
including governments, programmers, researchers and
community and civil society advocates.
Dialogue overview
The two-day forum began with discussions on systems that
support biomedical HIV prevention research. Presenters
gave an overview of past and present global efforts, and
how to harness the potential of these tools to prevent new
HIV infections, with a focus on Africa. There were discus-
sions on the potential impact of antiretrovirals for treat-
ment of people living with HIV, how to make eliminating
mother to child transmission of HIV a priority and reality
in Africa; building infrastructure to support ethical conduct
of biomedical HIV prevention research in Africa; and the
role of various players- such as civil society organisations,
community, academia and institutional review boards
(IRBs)- in the design and implementation of biomedical
HIV prevention research in Africa.
The second day of the conference allowed for more
in-depth discussion on the specific challenges associated
with engagement of populations in HIV prevention
research projects. This included presentations and dis-
cussions on engagement of young women, MSM, FSWs,
and PWID. The following is a summary of the discus-
sions and priorities of the different groups which
attended the conference.
Government leaders and programme implementers
Implementation of the Abuja +12 Declaration
Made in July 2013, when Heads of State of African
Union countries met to review efforts made towards
achieving the 2001 Abuja Declaration, the Abuja +12
Declaration [2] articulates need for an African Centre
for Disease Control and Prevention to conduct … life
saving research for priority health problems in Africa
and to serve as a platform to share knowledge and build
capacity in responding to the public health emergencies
and threats. The Abuja +12 Declaration includes com-
mitments to: accelerate the implementation of the 2001
Abuja Declaration [3]; review relevant laws and policies
at the national and regional levels to strengthen rights
based protection for all vulnerable and key populations;
increase access of young people to evidence-based com-
bination prevention programmes; promote the integra-
tion of HIV/AIDS services with sexual and reproductive
health services and tuberculosis interventions; accelerate
child and adolescent access to HIV treatment; and
intensify research on strengthening preventive measures
among others.
Local investment in prevention research
There has been no comprehensive accounting of African
governments’ investment in biomedical HIV prevention
research to date. However, with the exception of the South
African government, this investment has been negligible.
The US government remains the largest public-sector
investor in HIV prevention research in Africa, followed by
the European public sector [4]. Without significant financial
participation from African governments, the research
agenda risks focusing on donor governments’ priorities
rather than local needs.
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Consensus from the meeting was that governments in
Africa need to think strategically about how to support
biomedical research and development in ways that are evi-
dence-driven, cost-effective, and reflect local needs and
priorities. This would require investment in academic and
industrial research and development processes including
information technology (IT) and biotechnology research,
development of innovation clusters and state-of-the-art
core laboratories, tax incentives for research and develop-
ment, support of infrastructure development and payment
of competitive salaries. A national research agenda should
be relevant and feasible based on local data, and supported
by policies that promote the ethical conduct of research by
setting standards and guidelines, providing training and
support for ethics review committees, and supporting civil
society watchdog organizations [5].
Plans that promote specific biomedical interventions,
such as National HIV Vaccine Plans (NHVP), are less
effective than broader plans that seek to strengthen a
country’s capacity to contribute to research on a variety
of biomedical interventions and related programmes. The
NHVPs developed in 11 African countries have provided
clear rules on regulatory approval, scientific and ethical
reviews, biosafety and monitoring guidelines, and identi-
fied gaps to be addressed- all of which could be expanded
to promote a broader biomedical prevention research
agenda. Such plans should take into account lessons
learned from the challenges to implementation of
NHVPs in Africa, including unrealistic expectations and
reliance on external organizations such as the World
Health Organisation for funding [6].
Community and civil society stakeholders
Build stronger partnerships and seek conversations with
diverse stakeholders beyond trial communities
Until relatively recently, the understanding of “community
involvement” in HIV prevention research in Africa has,
with a few notable exceptions, tended to focus on the
immediate local communities where the trials are taking
place. Lessons learned from successful projects as well as
failures [7,8], including the cancelled PrEP trials of 2005
[9-12] demonstrate that a broader definition of “community
stakeholders” is required to maximize the benefits of bio-
medical prevention research. Prevention advocacy needs to
engage with national and regional media and opinion lea-
ders, policy makers and programmers, as well as commu-
nity organizations dealing with related issues beyond HIV
prevention. Seeking synergy with partners working on HIV
treatment and access is crucial in light of the growing body
of evidence on the use of antiretrovirals for HIV prevention,
such as TasP [13], and PrEP [14-17]. Similarly, the emer-
ging though inconclusive information about a possible con-
nection between hormonal contraceptive use and HIV risk
requires engagement between advocates and programmers
in the often separate fields of HIV prevention and family
planning [18,19].
Given the evidence of how gender issues affect HIV risk,
treatment-seeking and treatment adherence, it is crucial
that biomedical prevention advocates seek collaboration
with experts and organizations focused on gender and
women’s empowerment. Likewise, the benefit of biomedi-
cal HIV prevention interventions for key populations-
MSM, FSW, PWID - depends on effective policies that
reduce stigma, enhance access to services, strengthen eco-
nomic opportunities, and protect rights [20-22]. This will
require collaboration across sectors that serve and advo-
cate for these communities [23-25].
Develop a coherent advocacy agenda across biomedical
prevention research
A prevention paradigm that includes multiple methods
and indicators promotes effective synergies- for research,
for policy and for advocacy. Strategies and activities need
to be defined that cut across existing silos of activities
and promote a common action agenda. This agenda
would include advocacy for issues that affect all aspects
of HIV prevention research, such as: the definition of
standards of ethical practices, particularly ones suppor-
tive of research among key populations in dire need of
new HIV prevention tools; ethical processes for including
young adolescents in clinical research so that they can
potentially benefit from the resulting data, accountability
of national governments to commitments they have
made to fund health, HIV prevention and treatment, and
biomedical research [5,26].
Enhance community “research literacy.”
Community leaders and advocates also need to learn the
subtle redefined vocabulary for describing HIV preven-
tion trial processes and results to the community at
large- a vocabulary that is constantly evolving. Such
knowledge would contribute to meaningful engagement
of community members in research processes and facili-
tate the development of community champions for HIV
prevention research. Civil society organizations need to
drive and strengthen “research literacy” and engage with
researchers, institutions, and communities to enhance
dialogue and understanding of prevention research, and
research ethics [24].
Researchers, institutions, and trial sponsors
Establish a process for determining the appropriate
incentives for trial participants
The lack of guidance and consistency for determining
appropriate incentives that compensate trial participants
for their time and effort spent on HIV prevention research
without it representing undue inducement and jeopardiz-
ing voluntary consent is a real dilemma in the HIV pre-
vention field. Currently, most research projects do not
report on these incentives and so conducting an analytical
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study on what may be appropriate based on study reports
is difficult [27]. The field needs to look at creating a data-
base on incentives used in different trials, settings, popula-
tions and diseases, to which research stakeholders can
refer as they discuss, adapt and create incentive para-
meters for future studies [27].
All stakeholders
Engage with the larger research field
The impact of biomedical intervention on the epidemic
is inextricably linked to the context and reality of lives
of individuals and communities. It is important to
engage with the larger science, social science and other
research fields beyond the community of stakeholders
directly engaged with biomedical HIV prevention
research and development, in order to recognize
and actively address the social, economic, structural and
cultural factors that impact risk and behavior. The
importance of combining strategies that address the
behavioural, biomedical and structural needs of indivi-
duals at risk of HIV prevention cannot be overempha-
sized. Successful national and global HIV responses
need to move beyond the current efforts to medicalize
HIV prevention. Rather, biomedical strategies must be
well-situated within the context of the realities of the
daily lives of all stakeholders [28]. Such collective efforts
should be directed at seeking synergies and efficiencies
between concurrent, mutually reinforcing research, poli-
cies, and programmes [29].
Conduct research that reflects the realities of people’s lives
Research in-turn needs to address the reality of the HIV
experience and government response to the needs of its
citizens. Research must be implemented in ways that build
on lessons learned [30,31]. One of the realities is that peo-
ple’s lives are not situated in silos. Oftentimes a FSW, or
an MSM is also a drug user, and could be a person living
with HIV [22,23]. Responses therefore need to be dynamic
and flexible enough to adapt to the realities of the daily
lives of people affected by HIV.
Encourage and expand private sector contributions to the
national HIV/AIDS response
Such investment could include financial, skills, competen-
cies and other resources that contribute to the collective
response. So far, many national responses in Africa have
done little to effectively engage the local private sector.
Reliance on the donor community for the current and
future HIV response is not sustainable. Government own-
ership of national responses is a key part of the advocacy
agenda moving into the next decade [32].
Make cost-effective use of existing resources
New biomedical HIV prevention tools are expected to
complement the existing armamentarium for the HIV
response. As efforts are invested in the development of
new tools, efforts also need to be invested in learning how
to do increase access and utilization of existing tools. One
way is to collectively learn, understand and repair the
“leaks”- social, behavioral, and health system-related -
along the “pipeline” from undiagnosed HIV infection to
effective treatment. This way HCT, HIV treatment and
PMTCT coverage can be improved [33,34]. The conduct
of implementation research is one way to go. The lessons
we learn now should also help to increase access to new
tools, techniques and interventions for HIV prevention as
they are developed in the future [31].
Enhance community ownership of the HIV response
Institutionalize arrangements that strengthen community
ownership and contribution to care and support through
local institutions and state ownership of HIV/AIDS
response is also needed. Government leadership is critical,
but so also must national academia, communities and end
product users feel and have a sense of ownership of suc-
cesses and failures in the field [25,35]. An increased sense
of ownership will help facilitate roll-out of proven biome-
dical interventions as well as lay the groundwork for
further research into HIV vaccines and even an HIV cure
[31,36,37] which should indeed help “get to zero” and
eventually end the global HIV epidemic: a common goal
for those involved in the global HIV enterprise.
Conclusion
The implementation of biomedical HIV prevention
research has engaged African stakeholders for decades.
However, there has been very few opportunities and plat-
forms created to enable regional stakeholders to engage
with one another and discuss the required concrete con-
certed actions to facilitate active ownership of the imple-
mentation of HIV research on the continent. The 2013
BHPF held in Abuja, Nigeria in November 2013 made
important headway in identifying the key gaps, needs,
opportunities and next steps for action in the field of bio-
medical HIV prevention research in Africa. The forum
also created a platform that allowed for networking of sta-
keholders in the field enabling them to share resources,
best practices, challenges and experiences. By highlighting
key considerations for biomedical HIV prevention
research and development in Africa, the forum has helped
identify key advocacy issues that Civil Society can expend
efforts to strengthen support for future biomedical HIV
prevention research in the field on the continent.
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